CompletedNot Applicable

Implementation and Outcome of Minimally Invasive Pancreatoduodenectomy in Europe:

Netherlands1,336 participantsStarted 2019-01-01

Plain-language summary

A planned analysis of outcomes among consecutive patients after MIPD from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Data from all patients who underwent R-MIPD and L-MIPD between January 1st 2019 and December 31st 2021 were included Exclusion Criteria: * Other pancreatic procedures * Hybrid approaches (reconstruction phase open) * Procedures with insufficient baseline data / missing primary outcome data.

What they're measuring

Major morbidity

Timeframe: 30 days

30-day/in-hospital mortality.

Timeframe: 30 days

Trial details

NCT IDNCT06135233

SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Pancreas Disease trials